SCHEMBL4987570

SCHEMBL4987570

CC(C)(C#N)c1ccccc1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.46
ALOX15 P16050 3/20 0.46
CA12 O43570 3/20 0.41
CA1 P00915 3/20 0.41
CA2 P00918 3/20 0.41
CA4 P22748 3/20 0.41
CA7 P43166 3/20 0.41
CA9 Q16790 3/20 0.41
KDM4E B2RXH2 2/20 0.41
HMGB1 P09429 2/20 0.41
HPGD P15428 2/20 0.41
NAPRT Q6XQN6 2/20 0.41
CA6 P23280 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CA14 Q9ULX7 1/20 0.41
HSP90AA1 P07900 1/20 0.40
HSP90AB1 P08238 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.39
HDAC8 Q9BY41 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4967948 0.84 ALDH1A1 (0.42) ALDH1A1KDM4EHPGDSMN1; SMN2HSP90AA1
SCHEMBL3934344 0.83 ALOX15 (0.40) ALDH1A1ALOX15CA12CA1CA2
SCHEMBL825860 0.83 TSHR (0.49) ALDH1A1ALOX15KDM4EHPGDSMN1; SMN2
SCHEMBL5534100 0.81 TSHR (0.49) ALDH1A1ALOX15CA1CA2CA9
Water SCHEMBL2542359 0.80 ALDH1A1 (0.54) ALDH1A1ALOX15CA12CA1CA2
Ethylene SCHEMBL28047474 0.79 ALDH1A1 (0.52) ALDH1A1ALOX15CA12CA1CA2
SCHEMBL28494576 0.78 HSP90AA1 (0.39) SMN1; SMN2HSP90AA1HSP90AB1LMNATSHR
SCHEMBL31028133 0.78 ALDH1A1 (0.56) ALDH1A1ALOX15CA12CA1CA2
SCHEMBL2214094 0.78 ALDH1A1 (0.56) ALDH1A1ALOX15CA12CA1CA2
SCHEMBL39249 0.78 ALDH1A1 (0.56) ALDH1A1ALOX15CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023134712-A1 ANTIDIABETIC COMPOUNDS AND COMPOSITIONS REZUBIO PHARMACEUTICALS CO., LTD (CN) 2023-07-20 WO disclosed
EP-3728260-A1 EXO-AZA SPIRO INHIBITORS OF MENIN-MLL INTERACTION Janssen Pharmaceutica NV (BE) 2020-10-28 EP disclosed
WO-2018166528-A1 PYRIMIDINYL-PYRIDYLOXY-NAPHTHYL COMPOUNDS AND METHODS OF TREATING IRE1-RELATED DISEASES AND DISORDERS GENENTECH, INC. (US) 2018-09-20 WO disclosed
EP-1966159-A2 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2008-09-10 EP disclosed
WO-2007071963-A2 QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS ASTRAZENECA AB (SE) 2007-06-28 WO disclosed
WO-2006067445-A2 CSF-1R KINASE INHIBITORS ASTRAZENECA AB (SE) 2006-06-29 WO disclosed
EP-0625978-A1 PIPERAZINE AND PIPERIDINE DERIVATIVES, AND THEIR USE AS ANTIPSYCHOTICS THE WELLCOME FOUNDATION LIMITED (GB) 1994-11-30 EP disclosed
WO-1993016073-A1 PIPERAZINE AND PIPERIDINE DERIVATIVES, AND THEIR USE AS ANTIPSYCHOTICS THE WELLCOME FOUNDATION LIMITED (GB) 1993-08-19 WO disclosed